Asset profile
izokibep
Antibody-derived scaffold
Evidence outlook · registrational
Psoriatic Arthritis: registrational readout pending
Entered Phase 3 on partial signal mid-stage evidence. No upcoming registrational readout date is posted to the registry — check News for topline announcements.
NCT04713072: The study randomized 129 participants to two izokibep doses or placebo and masked participants, care providers, and investigators. Its primary endpoint was the clinical ACR50 response, but no primary outcome results are posted, so whether the treatment comparison was met or missed cannot be determined.
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.